Market Closed -
Nasdaq
01:30:00 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
5.05
USD
|
+2.64%
|
|
-6.83%
|
+11.73%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
22.8
|
106.5
|
111
|
156.8
|
81.56
|
91.13
|
-
|
-
|
Enterprise Value (EV)
1 |
22.8
|
106.5
|
111
|
156.8
|
81.56
|
91.13
|
91.13
|
91.13
|
P/E ratio
|
-7.3
x
|
-51
x
|
17.9
x
|
9.44
x
|
-4.61
x
|
-6.12
x
|
10.5
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.31
x
|
7.34
x
|
1.4
x
|
1.28
x
|
1.8
x
|
1.66
x
|
0.66
x
|
0.46
x
|
EV / Revenue
|
2.31
x
|
7.34
x
|
1.4
x
|
1.28
x
|
1.8
x
|
1.66
x
|
0.66
x
|
0.46
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
11,574
|
11,604
|
15,486
|
16,278
|
18,045
|
18,045
|
-
|
-
|
Reference price
2 |
1.970
|
9.180
|
7.170
|
9.630
|
4.520
|
5.050
|
5.050
|
5.050
|
Announcement Date
|
25/03/20
|
31/03/21
|
30/03/22
|
28/03/23
|
15/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
9.876
|
14.51
|
79.04
|
122.6
|
45.24
|
54.79
|
138.3
|
196.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-2.093
|
9.801
|
23.6
|
-21.61
|
-14.01
|
12.71
|
33.41
|
Operating Margin
|
-
|
-14.42%
|
12.4%
|
19.24%
|
-47.78%
|
-25.58%
|
9.2%
|
16.99%
|
Earnings before Tax (EBT)
1 |
-
|
-2.326
|
5.305
|
22.91
|
-22.8
|
-14.93
|
11.84
|
32.44
|
Net income
1 |
-
|
-2.125
|
6.273
|
18.46
|
-16.78
|
-14.93
|
11.84
|
32.44
|
Net margin
|
-
|
-14.64%
|
7.94%
|
15.05%
|
-37.1%
|
-27.26%
|
8.57%
|
16.5%
|
EPS
2 |
-0.2700
|
-0.1800
|
0.4000
|
1.020
|
-0.9800
|
-0.8250
|
0.4800
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/20
|
31/03/21
|
30/03/22
|
28/03/23
|
15/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.472
|
45.16
|
47.53
|
29.09
|
24.2
|
21.82
|
19.3
|
13.22
|
8.365
|
4.351
|
3.634
|
11.18
|
14.92
|
18.82
|
31.13
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.647
|
13.68
|
16.15
|
10.59
|
1.954
|
-5.09
|
0.875
|
-4.658
|
-6.478
|
-11.35
|
-8.298
|
-7.25
|
-6.65
|
-6.05
|
-
|
Operating Margin
|
-38.5%
|
30.29%
|
33.97%
|
36.39%
|
8.07%
|
-23.32%
|
4.53%
|
-35.24%
|
-77.44%
|
-260.91%
|
-228.34%
|
-64.88%
|
-44.56%
|
-32.14%
|
-
|
Earnings before Tax (EBT)
1 |
-3.978
|
9.621
|
15.91
|
10.41
|
1.778
|
-5.189
|
0.564
|
-4.914
|
-6.785
|
-11.66
|
-8.831
|
-7.45
|
-6.85
|
-6.25
|
-
|
Net income
1 |
-3.978
|
10.59
|
12.49
|
7.446
|
0.969
|
-2.444
|
0.55
|
-3.44
|
-5.141
|
-8.751
|
-6.265
|
-7.45
|
-6.85
|
-6.25
|
-
|
Net margin
|
-42%
|
23.45%
|
26.29%
|
25.59%
|
4%
|
-11.2%
|
2.85%
|
-26.03%
|
-61.46%
|
-201.13%
|
-172.4%
|
-66.67%
|
-45.9%
|
-33.2%
|
-
|
EPS
2 |
-0.2600
|
0.6600
|
0.6800
|
0.4000
|
0.0600
|
-0.0800
|
0.0300
|
-0.2000
|
-0.3000
|
-0.5100
|
-0.0700
|
-0.2450
|
-0.1700
|
-0.1300
|
0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
30/03/22
|
13/05/22
|
11/08/22
|
10/11/22
|
28/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
15/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
4.23
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
5.35%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/20
|
31/03/21
|
30/03/22
|
28/03/23
|
15/03/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +11.73% | 91.13M | | -16.58% | 8.49B | | +58.90% | 4.08B | | -39.78% | 2.42B | | -10.33% | 2.42B | | -8.91% | 2.33B | | -2.53% | 2.01B | | -19.90% | 1.53B | | -38.30% | 1.26B | | +2.19% | 1.07B |
Medical & Diagnostic Laboratories
|